Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 1
2010 1
2013 1
2014 2
2016 1
2017 1
2018 3
2019 6
2020 5
2021 4
2022 6
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study.
Kobayashi K, Ogasawara S, Maruta S, Okubo T, Itokawa N, Haga Y, Seko Y, Moriguchi M, Watanabe S, Shiko Y, Takatsuka H, Kanzaki H, Koroki K, Inoue M, Nakamura M, Kiyono S, Kanogawa N, Kondo T, Suzuki E, Ooka Y, Nakamoto S, Inaba Y, Ikeda M, Okabe S, Morimoto N, Itoh Y, Nakamura K, Ito K, Azemoto R, Atsukawa M, Itobayashi E, Kato N. Kobayashi K, et al. Among authors: watanabe s. Clin Cancer Res. 2023 Dec 1;29(23):4760-4769. doi: 10.1158/1078-0432.CCR-23-1462. Clin Cancer Res. 2023. PMID: 37796614
Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents.
Seko Y, Moriguchi M, Takahashi A, Yamaguchi K, Umemura A, Okuda K, Kataoka S, Unozawa H, Kobayashi K, Ogasawara S, Sato R, Tsuchiya S, Watanabe S, Morimoto N, Iwai K, Aramaki T, Kato N, Itoh Y. Seko Y, et al. Among authors: watanabe s. J Gastroenterol. 2022 Feb;57(2):90-98. doi: 10.1007/s00535-021-01837-5. Epub 2022 Jan 15. J Gastroenterol. 2022. PMID: 35031857
Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma.
Kobayashi K, Ogasawara S, Takahashi A, Seko Y, Unozawa H, Sato R, Watanabe S, Moriguchi M, Morimoto N, Tsuchiya S, Iwai K, Inoue M, Ogawa K, Ishino T, Iwanaga T, Sakuma T, Fujita N, Kanzaki H, Koroki K, Nakamura M, Kanogawa N, Kiyono S, Kondo T, Saito T, Nakagawa R, Suzuki E, Ooka Y, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Nagashima K, Kato J, Isoda N, Aramaki T, Itoh Y, Kato N. Kobayashi K, et al. Among authors: watanabe s. Liver Cancer. 2021 Dec 6;11(1):48-60. doi: 10.1159/000519868. eCollection 2022 Jan. Liver Cancer. 2021. PMID: 35222507 Free PMC article.
Conventional Therapies Do Not Prolong the Prognosis of Hepatocellular Carcinoma Patients with Extrahepatic Metastases under Receiving of Tyrosine Kinase Inhibitors.
Maeda H, Miura K, Morimoto N, Watanabe S, Tsukui M, Takaoka Y, Nomoto H, Goka R, Sato N, Morishima K, Sakuma Y, Sata N, Fukushima N, Isoda N, Yamamoto H. Maeda H, et al. Among authors: watanabe s. Cancers (Basel). 2022 Jan 31;14(3):752. doi: 10.3390/cancers14030752. Cancers (Basel). 2022. PMID: 35159018 Free PMC article.
29 results